Skip to main content
Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology 12/2008

01.12.2008 | Retinal Disorders

Assessment of selected adhesion molecule and proinflammatory cytokine levels in the vitreous body of patients with type 2 diabetes — role of the inflammatory–immune process in the pathogenesis of proliferative diabetic retinopathy

verfasst von: Joanna Adamiec-Mroczek, Jolanta Oficjalska-Młyńczak

Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology | Ausgabe 12/2008

Einloggen, um Zugang zu erhalten

Abstract

Background

The aim of the study is to demonstrate the participation of the inflammatory-immune process in the pathogenesis of proliferative diabetic retinopathy (PDR).

Methods

Twenty four women and 22 men with type 2 diabetes (mean age 63.97 ± 9.00 years, mean duration of diabetes 12.56 ± 6.87 years) were enrolled in the study. Serum concentrations of soluble forms of ICAM-1, VCAM-1 as well as IL-6 and TNF-α were evaluated in all study subjects. In 19 patients, simultaneous assessment of selected parameter levels in both serum and vitreous samples was performed. Vitrectomy was performed due to intravitreal hemorrhage, accompanied in some patients by traction retinal detachment. The control group consisted of 15 patients having undergone vitrectomy for reasons other than PDR. Tests were performed using the ELISA method.

Results

Serum and intraocular concentrations of sICAM-1, sVCAM-1, IL-6, TNF-α were considerably higher in study subjects with PDR than in controls. Simultaneously, a positive correlation was found between intraocular sVCAM-1 (r = 0.590, p = 0.007), TNF-α (r = 0.822, p < 0.001) concentrations and HbA1c levels. The above-mentioned dependence was not shown for sICAM-1 and IL-6 vitreous concentration. Local vitreous VCAM-1 level increase was also dependent on vitreous TNF-α concentration growth (r = 0.470, p = 0.043). No significant correlation was found between serum and vitreous levels of the selected parameters in the group of 19 patients with PDR.

Conclusions

Increase in sICAM-1 and sVCAM-1 levels, as well as their correlation with high vitreous IL-6 and TNF-α concentrations in patients with PDR, seem to confirm the inflammatory–immune nature of this process. In diabetes, inadequate metabolic control remains an important risk factor in the development of PDR.
Literatur
1.
Zurück zum Zitat Abiko T, Abiko A, Clermont AC (2003) Characterization of retinal leukostasis and hemodynamics in insulin resistance and diabetes. Diabetes 52:829–837PubMedCrossRef Abiko T, Abiko A, Clermont AC (2003) Characterization of retinal leukostasis and hemodynamics in insulin resistance and diabetes. Diabetes 52:829–837PubMedCrossRef
2.
Zurück zum Zitat Adamis AP (2002) Is diabetic retinopathy an inflammatory disease? Br J Ophthalmol 86:363–365PubMedCrossRef Adamis AP (2002) Is diabetic retinopathy an inflammatory disease? Br J Ophthalmol 86:363–365PubMedCrossRef
3.
Zurück zum Zitat Barouch FC, Miyamoto K, Allport JR, Fujita K, Bursell SE, Aiello LP et al (2000) Integrin-mediated neutrophil adhesion and retinal leukostasis in diabetes. Invest Ophthalmol Vis Sci 41(5):1153–1158PubMed Barouch FC, Miyamoto K, Allport JR, Fujita K, Bursell SE, Aiello LP et al (2000) Integrin-mediated neutrophil adhesion and retinal leukostasis in diabetes. Invest Ophthalmol Vis Sci 41(5):1153–1158PubMed
4.
Zurück zum Zitat Doganay S, Evereklioglu C, Er H, Turkoz Y, Sevinc A, Mehmet N et al (2002) Comparison of serum NO, TNF-α, IL-1β, sIl-2R, IL-6 and IL-8 levels with grades of retinopathy in patients with diabetes mellitus. Eye 16:163–170PubMedCrossRef Doganay S, Evereklioglu C, Er H, Turkoz Y, Sevinc A, Mehmet N et al (2002) Comparison of serum NO, TNF-α, IL-1β, sIl-2R, IL-6 and IL-8 levels with grades of retinopathy in patients with diabetes mellitus. Eye 16:163–170PubMedCrossRef
5.
Zurück zum Zitat Hernandez C, Burgos R, Canton A, Garcia-Arumi J, Segura RM, Simo R (2001) Vitreous levels of vascular cell adhesion molecule and vascular endothelial growth factor in patients with proliferative diabetic retinopathy: a case-control study. Diabetes Care 24(3):516–521PubMedCrossRef Hernandez C, Burgos R, Canton A, Garcia-Arumi J, Segura RM, Simo R (2001) Vitreous levels of vascular cell adhesion molecule and vascular endothelial growth factor in patients with proliferative diabetic retinopathy: a case-control study. Diabetes Care 24(3):516–521PubMedCrossRef
6.
Zurück zum Zitat Matsumoto K, Sera Y, Ueki Y, Inukai G, Niiro E, Miyake S (2002) Comparison of serum concentrations of soluble adhesion molecules in diabetic microangiopathy and macroangiopathy. Diabet Med 19(10):822–826PubMedCrossRef Matsumoto K, Sera Y, Ueki Y, Inukai G, Niiro E, Miyake S (2002) Comparison of serum concentrations of soluble adhesion molecules in diabetic microangiopathy and macroangiopathy. Diabet Med 19(10):822–826PubMedCrossRef
7.
Zurück zum Zitat Olson JA, Whitelaw CM, McHardy KC, Pearson DWM, Forrester JV (2002) Soluble leucocyte adhesion molecules in diabetic retinopathy stimulate retinal capillary endothelial cell migration. Diabetologia 40:1166–1171CrossRef Olson JA, Whitelaw CM, McHardy KC, Pearson DWM, Forrester JV (2002) Soluble leucocyte adhesion molecules in diabetic retinopathy stimulate retinal capillary endothelial cell migration. Diabetologia 40:1166–1171CrossRef
8.
Zurück zum Zitat Adamiec J, Oficjalska-Młyńczak J (2005) The role of cellular adhesion molecule in the development of proliferative diabetic retinopathy. Acta Ophthalmologica Polonica 107(4–6):330–333PubMed Adamiec J, Oficjalska-Młyńczak J (2005) The role of cellular adhesion molecule in the development of proliferative diabetic retinopathy. Acta Ophthalmologica Polonica 107(4–6):330–333PubMed
9.
Zurück zum Zitat Kao PC, Wu TJ, Ho LL, Li XJ (2000) Current trends and new approaches in the management of diabetes mellitus. Ann Clin Lab Sci 30:339–345PubMed Kao PC, Wu TJ, Ho LL, Li XJ (2000) Current trends and new approaches in the management of diabetes mellitus. Ann Clin Lab Sci 30:339–345PubMed
10.
Zurück zum Zitat Meleth AD, Agrón E, Chang CC, Reed GF, Arora K, Byrnes G, Csaky KG, Ferris FL, Chew EY (2005) Serum inflammatory markers in diabetic retinopathy. Invest Ophthalmol Vis Sci 46:4295–4301PubMedCrossRef Meleth AD, Agrón E, Chang CC, Reed GF, Arora K, Byrnes G, Csaky KG, Ferris FL, Chew EY (2005) Serum inflammatory markers in diabetic retinopathy. Invest Ophthalmol Vis Sci 46:4295–4301PubMedCrossRef
11.
Zurück zum Zitat Limb GA, Chignell AH, Green W, LeRoy F, Dumonde DC (1996) Distribution of TNF alpha and its reactive vascular adhesion molecules in fibrovascular membranes of proliferative diabetic retinopathy. Br J Ophthalmol 80(2):168–173PubMedCrossRef Limb GA, Chignell AH, Green W, LeRoy F, Dumonde DC (1996) Distribution of TNF alpha and its reactive vascular adhesion molecules in fibrovascular membranes of proliferative diabetic retinopathy. Br J Ophthalmol 80(2):168–173PubMedCrossRef
12.
Zurück zum Zitat Van Seventer GA, Shimizu Y, Horgan KJ, Shaws S (1990) the LFA-1 ligand ICAM-1 provides an important costimulatory signal for T-cell receptor-mediated activation of resting T cells. J Immunol 144:4579–4586PubMed Van Seventer GA, Shimizu Y, Horgan KJ, Shaws S (1990) the LFA-1 ligand ICAM-1 provides an important costimulatory signal for T-cell receptor-mediated activation of resting T cells. J Immunol 144:4579–4586PubMed
13.
Zurück zum Zitat Altmann DM, Hogg N, Trowsdale J, Wilkinson D (1989) Cotransfection of ICAM-1 and HLA-DE reconstitutes human antigen-presenting cell function in mouse L cells. Nature 338:512–514PubMedCrossRef Altmann DM, Hogg N, Trowsdale J, Wilkinson D (1989) Cotransfection of ICAM-1 and HLA-DE reconstitutes human antigen-presenting cell function in mouse L cells. Nature 338:512–514PubMedCrossRef
14.
Zurück zum Zitat Dougherty GJ, Murdoch S, Hogg N (1988) The function of human intercellular adhesion molecule-1 (ICAM-1) in the generation of an immune response. Eur J Immunol 18:35–39PubMedCrossRef Dougherty GJ, Murdoch S, Hogg N (1988) The function of human intercellular adhesion molecule-1 (ICAM-1) in the generation of an immune response. Eur J Immunol 18:35–39PubMedCrossRef
15.
Zurück zum Zitat Cukiernik M, Hileeto D, Evans T, Mukherjee S, Downey D, Chakrabarti S (2004) Vascular endothelial growth factor in diabetes induced early retinal abnormalities. Diabetes Res Clin Pract 65(3):197–208PubMedCrossRef Cukiernik M, Hileeto D, Evans T, Mukherjee S, Downey D, Chakrabarti S (2004) Vascular endothelial growth factor in diabetes induced early retinal abnormalities. Diabetes Res Clin Pract 65(3):197–208PubMedCrossRef
16.
Zurück zum Zitat Eastern and Southern European Region (2000) Recommendations for the management of patients with type 2 diabetes mellitus in the Central. Int Journ Postgraduate Train Med 8 Eastern and Southern European Region (2000) Recommendations for the management of patients with type 2 diabetes mellitus in the Central. Int Journ Postgraduate Train Med 8
17.
Zurück zum Zitat Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ (2003) Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42(6):1206–1252PubMedCrossRef Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ (2003) Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42(6):1206–1252PubMedCrossRef
18.
Zurück zum Zitat Schalkwijk CG, Chaturvedi N, Twaafhoven H, Van Hinsbergh VW, Stehouwer CD (2002) Amadori-albumin correlates with microvascular complications and precedes nephropathy in type 1 diabetic patients. Eur J Clin Invest 32:500–506PubMedCrossRef Schalkwijk CG, Chaturvedi N, Twaafhoven H, Van Hinsbergh VW, Stehouwer CD (2002) Amadori-albumin correlates with microvascular complications and precedes nephropathy in type 1 diabetic patients. Eur J Clin Invest 32:500–506PubMedCrossRef
19.
Zurück zum Zitat Schram MT, Chaturvedi N, Schalkwijk C, Giorgino F, Ebeling P, Fuller JH et al (2003) Vascular risk factors and markers of endothelial function as determinants of inflammatory markers in type 1 diabetes. Diabetes Care 26:2165–2173PubMedCrossRef Schram MT, Chaturvedi N, Schalkwijk C, Giorgino F, Ebeling P, Fuller JH et al (2003) Vascular risk factors and markers of endothelial function as determinants of inflammatory markers in type 1 diabetes. Diabetes Care 26:2165–2173PubMedCrossRef
20.
Zurück zum Zitat Monaco C, Paleolog E (2004) Nuclear factor κB: a potential therapeutic target in atherosclerosis and thrombosis. Cardiovasc Res 61:671–682PubMedCrossRef Monaco C, Paleolog E (2004) Nuclear factor κB: a potential therapeutic target in atherosclerosis and thrombosis. Cardiovasc Res 61:671–682PubMedCrossRef
21.
Zurück zum Zitat Schalkwijk CG, Stehouwer CDA (2005) Vascular complications in diabetes mellitus: the role of endothelial dysfunction. Clin Sci 109:143–159PubMedCrossRef Schalkwijk CG, Stehouwer CDA (2005) Vascular complications in diabetes mellitus: the role of endothelial dysfunction. Clin Sci 109:143–159PubMedCrossRef
22.
Zurück zum Zitat American Diabetes Association (2004) Clinical practice recommendations. Diabetes Care 27(Suppl.1) American Diabetes Association (2004) Clinical practice recommendations. Diabetes Care 27(Suppl.1)
23.
Zurück zum Zitat Bagg W, Ferri C, Desideri G, Gamble G, Ockelford P, Braatvedt GD (2001) The influences of obesity and glycemic control on endothelial activation in patients with type 2 diabetes. J Clin Endocrinol Metab 86:5491–5497PubMedCrossRef Bagg W, Ferri C, Desideri G, Gamble G, Ockelford P, Braatvedt GD (2001) The influences of obesity and glycemic control on endothelial activation in patients with type 2 diabetes. J Clin Endocrinol Metab 86:5491–5497PubMedCrossRef
24.
Zurück zum Zitat Klein R, Klein BEK (2002) Blood pressure control and diabetic retinopathy. Br J Ophthalmol 86:365–367PubMedCrossRef Klein R, Klein BEK (2002) Blood pressure control and diabetic retinopathy. Br J Ophthalmol 86:365–367PubMedCrossRef
25.
Zurück zum Zitat Zhang LY, Krzentowski GA, Lefebvre PJ (2001) Risk developing retinopathy in diabetes control and complications trial type 1 diabetic patients with good and poor metabolic control. Diabetes Care 23:1275–1279CrossRef Zhang LY, Krzentowski GA, Lefebvre PJ (2001) Risk developing retinopathy in diabetes control and complications trial type 1 diabetic patients with good and poor metabolic control. Diabetes Care 23:1275–1279CrossRef
26.
Zurück zum Zitat Freyberger H, Brocker M, Yakut H, Hammer J, Effert R, Schifferdecker E (2002) Increased levels of platelet-derived growth factor in vitreous fluid of patients with proliferative diabetic retinopathy. Exp Clin Endocrinol Diabetes 108:106–109CrossRef Freyberger H, Brocker M, Yakut H, Hammer J, Effert R, Schifferdecker E (2002) Increased levels of platelet-derived growth factor in vitreous fluid of patients with proliferative diabetic retinopathy. Exp Clin Endocrinol Diabetes 108:106–109CrossRef
27.
Zurück zum Zitat Matz R (2000) The target for good glycemic control should be an HbA1c concentrations of less than 0.07. West J Med 173:179–180PubMedCrossRef Matz R (2000) The target for good glycemic control should be an HbA1c concentrations of less than 0.07. West J Med 173:179–180PubMedCrossRef
28.
Zurück zum Zitat Őzmen B, Boyvada S (2003) The relationship between self-monitoring of blood glucose control and glycosylated haemoglobin in patients with type 2 diabetes with and without diabetic retinopathy. J Diabetes Complications 5:186–192 Őzmen B, Boyvada S (2003) The relationship between self-monitoring of blood glucose control and glycosylated haemoglobin in patients with type 2 diabetes with and without diabetic retinopathy. J Diabetes Complications 5:186–192
29.
Zurück zum Zitat Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA et al (2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35). BMJ 321:405–412PubMedCrossRef Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA et al (2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35). BMJ 321:405–412PubMedCrossRef
30.
Zurück zum Zitat Van Leiden HA, Dekker JJ, Moll AC, Nijpels G, Heine RJ, Bouter LM et al (2002) Blood pressure, lipids, and obesity are associated with retinopathy. Diabetes Care 25:1320–1325PubMedCrossRef Van Leiden HA, Dekker JJ, Moll AC, Nijpels G, Heine RJ, Bouter LM et al (2002) Blood pressure, lipids, and obesity are associated with retinopathy. Diabetes Care 25:1320–1325PubMedCrossRef
31.
Zurück zum Zitat Stratton IM, Kohner EM, Aldington SJ, Turner RC, Holmann RR, Manley SE et al (2001) UKPDS 50: risk factors for incidence and progression of retinopathy in type II diabetes over 6 years from diagnosis. Diabetologia 44:156–163PubMedCrossRef Stratton IM, Kohner EM, Aldington SJ, Turner RC, Holmann RR, Manley SE et al (2001) UKPDS 50: risk factors for incidence and progression of retinopathy in type II diabetes over 6 years from diagnosis. Diabetologia 44:156–163PubMedCrossRef
Metadaten
Titel
Assessment of selected adhesion molecule and proinflammatory cytokine levels in the vitreous body of patients with type 2 diabetes — role of the inflammatory–immune process in the pathogenesis of proliferative diabetic retinopathy
verfasst von
Joanna Adamiec-Mroczek
Jolanta Oficjalska-Młyńczak
Publikationsdatum
01.12.2008
Verlag
Springer-Verlag
Erschienen in
Graefe's Archive for Clinical and Experimental Ophthalmology / Ausgabe 12/2008
Print ISSN: 0721-832X
Elektronische ISSN: 1435-702X
DOI
https://doi.org/10.1007/s00417-008-0868-6

Weitere Artikel der Ausgabe 12/2008

Graefe's Archive for Clinical and Experimental Ophthalmology 12/2008 Zur Ausgabe

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Die Verwendung von Ophthalmika in der Schwangerschaft und Stillzeit stellt immer eine Off-label-Anwendung dar. Ein Einsatz von Arzneimitteln muss daher besonders sorgfältig auf sein Risiko-Nutzen-Verhältnis bewertet werden. In der vorliegenden …

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Vitrektomie Originalie

Die endogene Endophthalmitis ist eine hämatogen fortgeleitete, bakterielle oder fungale Infektion, die über choroidale oder retinale Gefäße in den Augapfel eingeschwemmt wird [ 1 – 3 ]. Von dort infiltrieren die Keime in die Netzhaut, den …

Bakterielle endogene Endophthalmitis

Vitrektomie Leitthema

Eine endogene Endophthalmitis stellt einen ophthalmologischen Notfall dar, der umgehender Diagnostik und Therapie bedarf. Es sollte mit geeigneten Methoden, wie beispielsweise dem Freiburger Endophthalmitis-Set, ein Keimnachweis erfolgen. Bei der …

So erreichen Sie eine bestmögliche Wundheilung der Kornea

Die bestmögliche Wundheilung der Kornea, insbesondere ohne die Ausbildung von lichtstreuenden Narben, ist oberstes Gebot, um einer dauerhaften Schädigung der Hornhaut frühzeitig entgegenzuwirken und die Funktion des Auges zu erhalten.   

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.